New study proves safety of novel, wireless pacing system, WiSE-CRT (Wireless Stimulation Endocardially for cardiac resynchronization therapy) two years after implantation. The study is the first to report on the medium-long term feasibility of the leadless pacing system for heart failure patients and was presented today at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions.
Search for "" returned 997 matches
The Heart Rhythm Society (HRS) issued an international consensus statement that comprehensively addresses lead management for patients with cardiovascular implantable electronic devices (CIEDs). The 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction was presented today at the 10th Asia Pacific Heart Rhythm Society (APHRS) Annual Scientific Session held in conjunction with the Annual Meeting of the Japanese Heart Rhythm Society (JHRS). The expert consensus statement is the first to have a comprehensive discussion of lead management issues, including lead extraction, and is an update to the 2009 HRS lead extraction clinical document.
A new study shows that the use of a wearable cardioverter defibrillator (WCD) is safe and effective in treating ventricular arrhythmias for pediatric patients who are at risk for sudden cardiac death (SCD). The study represents the largest pediatric patient population to date when evaluating the WCD as a therapy option. The findings of the study were presented today at Heart Rhythm 2017, the Heart Rhythm’s 38th Annual Scientific Sessions.
A new study found that dementia rates increase with delays in starting anticoagulation treatment for atrial fibrillation (AF). The large study included more than 76,230 AF patients with no prior history of dementia that were treated with an antiplatelet or warfarin. The results were presented today at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions, and show that warfarin, in particular, can increase the risk of dementia long-term.
A new study shows that the Apple Watch's heart rate sensor, when paired with an artificial intelligence-based algorithm, can detect a serious and often symptomless heart arrhythmia, atrial fibrillation (AF). The new research uses a deep neural network based on photoplethysmographic (PPG) sensors commonly found in smart watches. The results of this study were presented today at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions.
Working in concert, the Society for Cardiovascular Angiography and Interventions (SCAI), the Heart Rhythm Society (HRS), the Alliance of Cardiovascular Professionals (ACVP) and the Intersocietal Accreditation Commission (IAC) announce the release of the IAC Cardiovascular Catheterization accreditation program. Representatives from these organizations, as well as pediatric cardiologist and nurse members-at-large, have developed standards and created the accreditation process. The program establishes quality metrics and provides a rigorous evaluation through clinical peer review of the facility’s processes, documentation, and imaging critical to quality patient care as it relates to cardiovascular catheterization procedures.
Atrial fibrillation (AFib) is an abnormal heart rhythm. The four chambers of the heart usually beat in a steady, rhythmic pattern. AFib means that the atria (upper chambers of the heart) are fibrillating or twitching quickly and creating an irregular rhythm.
Heart Rhythm 2018 will take place May 9-12 at Boston Convention & Exhibition Center in Boston, MA. All media inquiries regarding the Society's 39th Annual Scientific Sessions should be directed to firstname.lastname@example.org .
The Heart Rhythm Society (HRS), through its efforts during Atrial Fibrillation Awareness Month in September and throughout the year, is working to increase public knowledge of AFib, including its symptoms, warning signs, and available treatment options.
BOSTON – Initial results from the International Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS (EFFORTLESS) subcutaneous implantable defibrillator (S-ICD System) Registry shows that the latest heart device, the S-ICD System, is performing appropriately in real-world circumstances and continues to show positive results in patients. Data analyzed from the largest study of real world experience using the S-ICD System to-date, demonstrated a conversion rate >98% for induced and ambulatory ventricular tachycardia or fibrillation (VT/VF), consistent with transvenous ICD systems.